Pedal To Metal: WuXi Drives Up Greater China Healthcare Ambitions
This article was originally published in PharmAsia News
Executive Summary
Stepping out of its core lab discovery, contract research and manufacturing services into genomics, e-commerce and clinical screening testing, WuXi PharmaTech is fast moving an aspiration to seize broader opportunities in the China healthcare market. But analysts wonder whether its bread-and-butter pharma and biologics customers are on board.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.